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The largest kindred with inherited prion disease P102L, historically Gerstmann-Stra« ussler-Scheinker syndrome,
originates from central England, with e¤ migre¤ s now resident in various parts of the English-speaking world.
We have collected data from 84 patients in the large UK kindred and numerous small unrelated pedigrees to
investigate phenotypic heterogeneity and modifying factors.This collection represents by far the largest series
of P102L patients so far reported. Microsatellite and genealogical analyses of eight separate European kindreds
support multiple distinct mutational events at a cytosine-phosphate diester-guanidine dinucleotide mutation
hot spot. All of the smaller P102L kindreds were linked to polymorphic human prion protein gene codon 129M
andwere not connected by genealogy ormicrosatellite haplotype background to the large kindred or each other.
While many present with classical Gerstmann-Stra« ussler-Scheinker syndrome, a slowly progressive cerebellar
ataxia with later onset cognitive impairment, there is remarkable heterogeneity. A subset of patients present
with prominent cognitive and psychiatric features and some have met diagnostic criteria for sporadic
Creutzfeldt-Jakob disease. We show that polymorphic human prion protein gene codon 129 modifies age at
onset: the earliest eight clinical onsets were all MM homozygotes and overall age at onset was 7 years earlier
for MM compared with MV heterozygotes (P=0.02).Unexpectedly, apolipoprotein E4 carriers have a delayed
age of onset by10 years (P=0.02).We found a preponderance of female patients comparedwithmales (54 females
versus 30 males, P=0.01), which probably relates to ascertainment bias.However, thesemodifiers had no impact
on a semi-quantitative pathological phenotype in 10 autopsied patients.These data allow an appreciation of the
range of clinical phenotype, modern imaging and molecular investigation and should inform genetic counselling
of at-risk individuals, with the identification of two genetic modifiers.
Keywords: P102L; sCJD; early-onset dementia; Gerstmann-Stra« ussler-Scheinker syndrome; prion disease
Abbreviations: APOE=apolipoprotein E; GSS=Gerstmann-Stra« ussler-Scheinker syndrome; IPD= inherited prion disease;
NCS=nerve conduction studies; OPRI=octapeptide repeat insertion; PRNP=human prion protein gene; PrPc=prion
protein (cellular isoform); PrPSc=prion protein (scrapie isoform); sCJD=sporadic Creutzfeldt-Jakob disease
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Introduction
Prion diseases occur uniquely in sporadic, acquired and
inherited forms. Inherited prion disease (IPD) accounts for
around 15% of all human prion disease (Collinge, 2005).
IPD also forms a significant proportion of familial young
onset dementia (Finckh et al., 2000). The longer average
duration of IPD, and need for genetic counselling of at-risk
family members, results in a larger impact on health service
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and social care providers when compared with other forms
of prion disease. IPD is associated with point mutations in
the human prion protein gene (PRNP), premature stop
codon mutations and alteration in the number of octapep-
tide repeat insertions (OPRI) in the unstructured region of
the N-terminal domain (Mead, 2006).
The P102L mutation has classically been associated with
Gerstmann-Stra¨ussler-Scheinker syndrome (GSS). This is
characterized clinicopathologically by onset of cerebellar
ataxia with dementia occurring much later and is associated
with multicentric PrP amyloid plaques in the cerebellum
and cerebral cortex. There is considerable heterogeneity,
however, even between first-degree relatives, which has led
to delayed diagnosis in those not presenting with typical
GSS. The heterogeneity in age at onset, clinical symptoms
and pathological findings raises questions about modifying
factors that may play a role in other aetiologic categories
of prion diseases and other forms of neurodegenerative
disease. Phenotypic variability even within the same IPD
P102L family does not always reflect the classical symptom
pattern or pathological changes (Hainfellner et al., 1995;
Piccardo et al., 1998; Arata et al., 2006). It is for this reason
that recent descriptions have favoured the use of a molec-
ular genetic classification rather than the traditional clinico-
pathological ones (Collinge et al., 1992, 2005). Explanations
for this heterogeneity have begun to emerge, although the
reasons for it remain largely unexplained (Parchi et al.,
1998; Wadsworth et al., 2006).
The large family from central England, originally referred
to as the ‘W’ kindred, was first reported 30 years ago with
an unusual inherited neurodegenerative disease (Cameron
and Crawford, 1974). While autosomal dominant trans-
mission was recognized early on, an atypical form of
Huntington’s disease was suspected to be responsible. The
observation that a member of the family presented with the
classical clinical and neuropathological features of sporadic
Creutzfeldt-Jakob disease (sCJD) was confused when other
affected family members fitted neither clinical nor patho-
logical criteria for this disease (Rosenthal et al., 1976). An
inherited susceptibility to neurological disease of different
types including sCJD was therefore postulated (Rosenthal
et al., 1976; Adam et al., 1982). Following the demonstra-
tion that these heritable disorders may also be transmissible
to experimental animals (Masters et al., 1981), the possibil-
ity of an agent originating in the genome, and not requiring
exogenous aetiological factors for its development, was
proposed (Baker et al., 1985). In 1989, linkage of the P102L
PRNP mutation to GSS in members of this kindred was
reported (Hsiao et al., 1989), only the second reported
mutation in a neurodegenerative disease [the earlier being
the report of a six OPRI PRNP mutation in another
kindred (Owen et al., 1989)].
In this article, we present genetic and genealogical
investigation of multiple international P102L pedigrees
that we have identified over 17 years of PRNP diagnostic
testing in London. Microsatellite and genealogical analyses
have allowed us to build an updated and expanded family
tree for the ‘W’ kindred, the largest P102L kindred reported
to date. Additionally, we present genealogical and molecular
evidence of multiple independent P102L mutations from
the United Kingdom and elsewhere in the English-speaking
world. This large collection of a rare inherited disease
documents the modern neurological and molecular inves-
tigations and marked phenotypic variability of P102L prion
disease. A genetic correlation with clinical and pathological
parameters has also been made, identifying two previously
uncharacterized modifiers of the phenotype of this
mutation.
Materials and Methods
Clinical information
For recent patients, a standardized history and examination
was performed either in hospital, where additional investigations
such as MRI and EEG were carried out, or on domiciliary visits.
Peripheral neurophysiological examinations were performed if
clinically indicated by dysaesthesiae or lower motor neuron signs.
Neuropsychological assessments were also carried out where
patients consented to them. Routine investigations and investiga-
tions into other potential causes of neurological deterioration
had often been carried out before diagnosis was reached and the
results of these were sought. For historical patients, clinical
histories and examination details were obtained where possible
from medical notes completed at the time of clinical review. In
some patients, notes had been destroyed prior to the beginning of
this study and information on presentation and cause of death was
sought from relatives and death certificates. Historical patients in
whose cases tissue did not survive for DNA analysis have been
considered affected if there is evidence of a neurological disease
causing paralysis, cerebellar features and/or dementia occurring
before the age of 65 years without an alternative cause being
established. Patients were classified based on current neurological
assessment or medical records, according to their presenting
features. Individuals who presented with prominent cognitive or
psychiatric features were contrasted with those without such
features, who tended to present with unsteadiness and weakness in
the absence of frank cognitive or psychiatric features.
Genealogical investigations
Genealogical work was carried out on all P102L patients from
the English-speaking world with tissue samples and/or clinical
information donated to the MRC Prion Unit, London. This was
initially limited to family tree information from the informant
(patient or relative). Further work was carried out where a geo-
graphical proximity to a known patient from the ‘W’ kindred was
established and later where microsatellite haplotyping suggested a
common haplotype to an extant patient. Information was gathered
from census returns; birth, marriage and death certification as well
as parish records; and work-house, asylum and hospital records,
where these could be traced. The results of clinical investigations
were sought where hospital notes survived. Pathological reports
have been sought where no tissue survives for examination using
modern techniques.
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Molecular analysis and investigations
DNA was extracted from peripheral blood lymphocytes, and
in some patients from frozen post-mortem brain tissue, using
Nucleon Blood DNA kit or a modified phenol–chloroform
extraction. The open reading frame was screened for the presence
of deletions or insertions in PRNP using size fractionation of
a PCR amplicon. The PRNP open reading frame was sequenced
using an ABI-377 automated DNA sequencer. All previously
identified P102L patients with DNA stored in the MRC Prion Unit
where research consent had been given underwent PRNP locus
haplotype analysis using 12 microsatellites on chromosome 20,
3–6 Mb (NCBI Entrez-gene mapviewer, http://www.ncbi.nlm.nih.
gov/sites/entrez). PCR using fluorescent primers specific for the
microsatellite regions were carried out followed by size discrimi-
nation on an acrylamide gel using MegaBace sequence analyser 3.0
software (Amersham Biosciences, 2001). Microsatellite haplotypes
were determined empirically from pedigree information. Statistical
work was carried out using SPSS version 12.0.1 for Windows
(SPSS.com) and Excel software (Microsoft). Estimates of effect size
were made by linear regression analysis. Statistical genetic analysis
used PLINK software (version 0.99, http://pngu.mgh.harvard.edu/
purcell/plink/).
Neuropathology
Five of the 10 patients described here have had neuropathology
reported previously, primarily before the availability of PrP
immunohistochemistry (Rosenthal et al., 1976; Adam et al.,
1982). Samples were taken from formalin-fixed brain, where
available. Cortex (frontal and occipital), basal ganglia and cerebel-
lum were sampled. Tissue was fixed in 10% buffered formal saline,
followed by incubation in 98% formic acid for 1 h. Following
further washing for 24 h in 10% buffered formal saline, tissue
samples were processed and embedded in paraffin wax. Sections
were cut at a nominal thickness of 4 mm, treated with 98% formic
acid for 5 min and then boiled in a low ionic strength buffer
(2.1 mM Tris, 1.3 mM EDTA, 1.1 mM sodium citrate, pH 7.8) for
20 min. All blocks were stained with haematoxylin and eosin and
with immunohistochemistry using anti-PrP monoclonal antibodies
ICSM18 (1:10 000 dilution of a 1 mg/ml solution) which labels
mutant and wild-type PrP and ICSM35 (1:3000 dilution of a
3 mg/ml solution) which labels only wild-type PrP (D-Gen,
London) and were incubated at 42C for 32 min. Haematoxylin
was used as the counterstain. Haematoxylin and eosin staining of
serial sections was done using conventional methods. Appropriate
controls were used throughout.
Samples were examined by the same pathologist (S.B.), blinded
to clinical details, and comparisons made between them. A semi-
quantitative scale was used to grade spongiform change and PrP
deposition (Fig. 1). Diffuse and plaque-related PrP deposition was
documented and contrasted. Clinicopathological comparisons
were made following this, with note being made of phenotype,
PRNP codon 129 and apolipoprotein E (APOE) genotypes.
Results
Genealogy and genetic studies
of shared ancestry
Eighty-four patients were identified from what were initially
considered to be 15 separate kindreds. Sixty of these
patients presented for the first time, while six are patients
who were reported previously but in whose cases significant
additional information has been obtained and is presented
here. Twenty-two of the total 84 patients, including mem-
bers of 14 kindreds, had been seen at the National Prion
Clinic or on domiciliary visits by clinic staff. Eight were
seen and examined by T.W. Of the remaining 62 patients,
5 are contemporary patients seen at other neurological
centres and where DNA or tissue samples and clinical data
has been supplied with patients’ consent and ethics com-
mittee approval. Fifty-seven patients are historical, typically
being the ancestors of contemporarily identified patients, in
whom a diagnosis of young onset neurological disease had
been made or had been reported by immediate descendents
(see Materials and methods section). Among the historical
patients, a variety of clinical diagnoses had been applied
and were obtained from hospital notes and death certi-
ficates (Table 1). While diagnostic labels have changed over
time, those used still provide information about predomi-
nant symptoms and clinical impressions of physicians at
the time.
A mutation-associated microsatellite haplotype for the
UK IPD P102L ‘W’ kindred was determined (Fig. 2). Five
smaller unrelated kindreds shared this haplotype, support-
ing the existence of a recent common ancestor for all of
these patients (shown as kindred 1 in Fig. 3). Further, IPD
P102L patients did not share a haplotype with either the
large kindred or with each other, suggesting that separate
mutational events had been responsible for their occurrence
(kindreds 2–9, Fig. 4). A final kindred where no DNA was
obtainable for haplotyping is not included in Fig. 4.
Following the identification of a common mutation-
associated haplotype, genealogical work in three patients
directly established links by common ancestor with the
‘W’ kindred. Two other families, which shared a haplotype,
could not be linked directly to the ‘W’ kindred. In
both patients, ancestors were identified in the same or
neighbouring villages to the original ‘W’ kindred. In one
family, an illegitimate ancestor provides a likely link;
his mother was living adjacent to a known member of
the ‘W’ kindred, according to contemporary census entries.
The inability to link in the final family genealogically may
relate to illegitimacy or alternatively may be explained
by a common ancestor prior to the end of the 18th
century, when the earliest identified shared relatives for the
‘W’ kindred were living. Emigration by family members
accounts for the identification of related individuals
in other parts of the English-speaking world: Canada,
the United States and Australia. Migration to other parts
of the United Kingdom explains the lack of geographical
proximity to known patients in recent generations and
the failure up to now to recognize the common ancestry
without supportive genetic evidence of common micro-
satellite haplotype. The genealogical work performed
suggests an earliest common ancestor for the presented
patients born in the mid-eighteenth century. However, the
mutation itself may have originated before this time.
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Clinical findings
Following microsatellite and genealogical studies, 40 new
patients were identified from the ‘W’ kindred, likely to be
associated with the P102L PRNP mutation. Twenty-eight
further patients from nine separate European kindreds
apparently not related to each other or to the ‘W’ kindred
are also presented. A full list of the major clinical findings
is provided in Table 2. Details on each patient are also
provided in Appendix 1 of Supplementary data, except in
cases of patients previously reported or where patients are
still living and details have not been included for the sake
of confidentiality.
The most commonly occurring primary presenting
features were unsteadiness (present in 72% of patients),
cognitive symptoms (28%) and leg weakness (22%).
Less common were leg pains or dysaesthesiae (16%) and
severe psychiatric features (10%). New onset deafness,
epileptic seizures, parkinsonism and diplopia occurred as
presenting features in individual patients (2% of patients
where data were available) (Fig. 5).
The commonest clinical syndrome was progressive
cerebellar ataxia associated with leg weakness and areflexia,
similar, but not identical to, the classical GSS phenotype.
Indeed, cerebellar signs were present in nearly all of the
patients where information could be obtained at some
point in the illness (98%). Cognitive features were usually
mild initially and developed later in the illness course.
Cognitive features were eventually present, however, in the
large majority of patients at some point during the disease
where information was available (81%), although in many
Fig. 1 Representative histology from P102L patients showing appearances graded semi-quantitatively. (A,C and E) show progressively
worsening degrees of spongiform change on haematoxylin and eosin stain of brain slices. (B,D and F) show increasing levels of plaque
deposition, as demonstrated by immunohistochemistry with anti-PrP antibody ICSM 35.Views in the left-hand column do not
necessarily correspond to the same region as the right column. A,C and D are from Patient 2.VII.2.B and E are from Patient VII.4,
while panel F is from Patient 3.VIII.1. The scaling bar shown is 100mM.
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patients these were mild. Lower motor neuron pattern leg
signs with areflexia, often associated with objective evidence
of muscle weakness and myopathic gait, was present in the
majority of patients (79%) (Fig. 6). In one patient (4.VII.1),
frank lower limb fasiculations were observed. Sensory
symptoms in the legs were also common, with dysaesthesiae
and hyperaesthesiae being frequently described by affected
patients (69%). Extrapyramidal features, especially parkin-
sonism and severe psychiatric symptoms such as personality
change, delusions, paranoia and visual hallucinations,
occurred in around half of patients (48 and 47% of
patients, respectively). Apraxia, however, in contrast with
patients with PRNP insertional mutations (Collinge et al.,
1992, 2005; Mead et al., 2006), was recorded in only
a single individual. Myoclonus and seizures occurred in a
minority of patients, although still relatively common
(36 and 7%, respectively). One patient (VII.2) presented
with a prominent generalized dystonia in addition to a
cerebellar ataxia. This has not been reported previously in
association with IPD P102L and the unusual phenotype in
this patient delayed diagnosis until post-mortem examina-
tion of brain tissue. No reports of choreic movement
disorders or of the dyspraxia and premorbid personality
changes commonly reported in some other forms of IPD
were obtained (Collinge et al., 1992; Mead et al., 2006).
Table 1 Listed causes of death from certificates for
historical patients of P102L IPD
Diagnosis Number of
patients
Disseminated sclerosis 6
Cerebellar degeneration 4
Paralysis 3
Cerebral degeneration 1
Cerebral and cerebellar cortical atrophy 1
Spinal cerebellar atrophy 1
Progressive cerebellar ataxia 1
Hereditary progressive ataxia 1
Olivo-ponto-cerebellar degeneration 1
Huntington’s chorea 1
Heredo-familial muscular dystrophy 1
Neurofibromatosis 1
Intracranial haemorrhage 1
Binswanger’s encephalitis 1
Multiple cerebrovascular accidents 1
Senile dementia 1
Schizophrenia 1
These are listed by frequency. For the many examples with only
one individual each given this diagnosis, they have been listed
loosely by type in the following order: cerebellar lesion implicated,
genetic causes, vascular causes, cognitive/psychiatric and other.
Fig. 2 Microsatellite genotypes for P102L IPD patients at 13 loci linked to codon 129. Shown left to right 50 ^30 with their physical
distance from codon 129 below. PRNP is situated between D20S97 and D20S895.VI.14 is a member of the original ‘W’ kindred. Below are
representative individuals from the five kindreds sharing a microsatellite background. The disease-associated haplotype is shown in bold.
The bottom half of the diagram shows the microsatellite genotypes of representatives of the other eight P102L kindreds. Although it has not
been possible to derive a mutation-associated haplotype for these, none appear to share a haplotype with the ‘W’ kindred or with each
other.
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There was a considerable heterogeneity regarding clinical
features. Although a majority of patients presented with
the phenotype of progressive ataxia with a later onset of
cognitive involvement, a significant subset presented with
predominantly psychiatric and cognitive features that often
remained the major clinical feature, in spite of the later
development of cerebellar and other physical signs. A still
smaller subset presented with a dementing illness having a
rapid and more global pattern of deficits reminiscent of
sCJD. In five of the patients presented here, where rapid
onset and uncertain or absent family history complicated
the clinical picture (VI.15, VI.9, VII.7, 4.VII.1 and 6.VIII.1),
the diagnosis of sCJD was considered; indeed, one patient
(VI.9) met World Health Organisation’s diagnostic criteria
for probable and the others possible sCJD.
Mean age at onset was 50 years (range 27–66 years, SD 9.4)
while mean age at death was 55 years (range 33–69 years,
SD 8.7). Mean duration of illness was 49 months but the
range was very wide (7–132 months, SD 26.1). The mutation
appears to have occurred in all the patients presented, linked
to the commoner PRNP codon 129 methionine allele. As a
result, all the patients where genotyping was performed
were methionine homozygotic (MM) or methionine/valine
heterozygotic (MV). Evidence from some other forms of
IPD (but not previously for P102L) shows that codon 129
homozygotes have an earlier age at onset and death than 129
heterozygotes (Collinge et al., 1992; Dlouhy et al., 1992;
Mead et al., 2006). Among the P102L patients reported here,
MM homozygotes have an earlier age at onset compared with
MV heterozygotes (47.3 10.2 versus 54 5.7, P= 0.02, t-test
Fig. 3 Pedigree of the original ‘W’ kindred (in grey) with newly identified and linked kindreds (in black).Only presumed affected
patients (filled symbols) or those thought to have transmitted the mutation but not known to be affected (empty symbols) have been
included for the sake of simplicity and confidentiality. All of the new patients have been linked genealogically to the original family with
the exception of the two small pedigrees on the right of the diagram where possible links are represented with a question mark.
Members of these kindreds both share a microsatellite background with the ‘W’ kindred and have ancestors closely located geographically
to them. Possible reasons for the inability to uncover an exact link genealogically are discussed in the text.
Fig. 4 Eight further family trees (six from the UK, two from elsewhere in Europe). Microsatellite haplotype analysis from these patients
suggests that none is related to the ‘W’ kindred or to each other. Separate mutational events are therefore likely to have been responsible.
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Table 2 Clinical features from P102L IPD patients reported
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II.3 F 40 40 7 ++ (+)
III.3 M F 53 ++
III.4 M F 52 Severe depression ++ (+)
III.5 F F 68 (+)
IV.2 M (M) 64 (+)
IV.3 F M 55 +
IV.4 F M 55
V.1 M 54
V.2 F (F)
V.3 F (F) 58 Fall, psychiatric changes + (+)
V.4 M (F) 69 Slurred speech,
difficulty walking
(+) (+)
V.6 F F 58 Slurred speech,
difficulty walking
 +
V.7 M F 47 52 60 Unsteadiness + + +
V.8 F F 46 49 36 + + +
V.9 F F 66 69 36 Pain in legs,
difficulty walking
+ + +
V.10 F F 56 +
V.11 F F 61 61 7 Leg weakness     +     
V.12 M F 60 +
V.13 F F 61
V.14 F F 60
V.15 F F 62 Unsteadiness,
weakness in legs
VI.1 M F 49 54 72 MV Seizure, personality
change
++ +  + + +  +
VI.2 F M 63 66 58 MM Unsteadiness, falls + +  + ++  +   
VI.4 M F 66 67 36 Unsteadiness, deafness + + + + 
VI.5 F F 54 65 132 Leg weakness
and numbness
+ ++ +  ++
VI.6 F F 57 60 36 Leg weakness + ++ + ++ ++ +
VI.7 M F 60 63 36 Forgetfulness + +
VI.8 F M 48 53 60 Unsteadiness ++ + ++ +
VI.9 M M 42 43 13 Unsteadiness ++ + + ++ + +  
VI.10 F F 50 53 25 Walking problems,
leg weakness
+ ++ + ++
VI.11 F F 39 45 61 Depression, memory loss  + + +
VI.12 F F 48 51 26 MV Left arm tremor,
cognitive decline
 ++  + () 
VI.13 F F 57 63 72 MM Unsteadiness,
difficulty running
+ +  + +  +   
VI.14 F F 65 69 48 Gait and writing problems  + ++ + + ++ + +  
VI.15 M F 58 58 8 MV Irritability, cognitive decline +  + + + +   
VI.16 F F 58 62     +     
VII.1 F F 27 33 60 MM Unsteadiness + + + ++ ++ + +
VII.2 M (F) 47 ++
VII.3 M F 43 47 48 Unsteadiness + + + ++
VII.4 F F 40 46 72 MM Sensory symptoms, gait  +  ++ ++  + ++  
VII.5 M F 63 64 12 MM Writing and gait difficulties   +  + + + +  
VII.6 M F 57 MM Unsteadiness   ++ +  + +  
VII.7 M F 37 39 25 MM Irritability, unsteadiness ++ +  ++ ++     
VII.8 F F 58 MM Cognitive decline + ++   +    
VII.10 M (F) 56 61 60 MV Unsteadiness,
cognitive decline
+ +  + ++
(continued)
2638 Brain (2008), 131, 2632^2646 T. E. F.Webb et al.
Table 2 Continued
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VII.12 M (M) 65
VII.13 F (M) 59 66 84 Unsteadiness, falls,
pain in legs
+  ++ + ++  ++  
VII.14 F (M) 61
VII.15 F (M) 55 (++)
VII.16 F (M) 37 Eccentric behaviour (++)
VII.17 F (M) 47 53 72 Unsteadiness,
cognitive decline
 +  (+) + (+)  
VII.18 M (M) 62 +
VIII.1 F M 44 49 60 MV Cognitive decline + () ()
VIII.2 M F 52 MM Unsteadiness,
leg weakness
   ++ + + ++ ++  
VIII.3 M F 56 MV Unsteadiness,
leg numbness
  + ++ ++ + ++ ++  
VIII.4 F M 63 67 48 MV Cognitive decline,
unsteadiness
++ ++ +  + + ++  + 
VIII.5 F M 60 MV Difficulty walking,
leg weakness
   + +  +  
VIII.6 F M 53 60 85 MV Diplopia, tinnitus,
leg weakness
 + + + + + 
2.VI.1 F  50 55 60
2.VII.1 F F 41 49 96 MM Unsteadiness,
dysphagia
+ +
2.VII.2 M F 52 58 72 MM Unsteadiness
and dysarthria
 +  + ++  ++ +  
2.VIII.1 F F 41 45 48 MM +
2.VIII.2 F F 34 39 56 MM
2.VIII.3 F F 35 MM
3.IV.1 F 55 57 24 (+)
3.V.1 F F 55 57 24 (+)
3.VI.1 M F 42 (++)
3.VII.1 F 36 39 36          
3.VIII.1 M F 48 53 60 MV Unsteadiness, leg pain + ++ ++ ++ ++ + ++   
4.VII.1 F F 57 59 28 MV Unsteadiness,
cognitive decline
++ + + + ++  ++ +  
5.VII.1 F (F) 42 (+)
5.VII.2 M 47 Unsteadiness and
memory loss
+ +
5.VIII.1 F M 38 45 43 MM Memory loss,
unsteadiness
+ + + + +  
6.VIII.1 F 45 45 7 MM Pain in limbs,
blurred vision
+ + + + + + + ++  
7.VIII.1 F 42 49 89 MM Unsteadiness  + + + ++  + ++  
8.VII.1 F
8.VIII.1 M F 57 61 46 MV Unsteadiness and
memory loss
  +  ++  + +  
8.VIII.2 F F 54 (+)
8.VIII.3 M F 57 (+)
9.VII.1 F 58 Memory loss with
pain in legs
(+) (+) (+)
9.VIII.1 F F 54 Unsteadiness (+)
9.VIII.2 F F 53 MM Unsteadiness,
falls, dysarthria
 +  + ++  ++ ++  
10.1 M F 37 43 64 Unsteadiness ++ + +
10.2 M M 47 50 42 MM Unsteadiness  +  + ++  + ++  
‘+’ denotes record of a feature being present. ‘++’ is used where clinicians have recorded findings as ‘severe’ or ‘marked’ or where deficit has
interfered with independence.‘’ denotes a feature mentioned as being absent by clinicians. Missing data is represented by a blank. Data relying on
inference from death certificate details or family memories are surrounded by brackets.
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heteroscedastic). When individuals with known codon 129
genotype were ranked by age at onset, the youngest eight
(n= 31) were codon 129MM. In addition, the standard
deviation in age at onset and death for codon 129MM was
much wider than that for codon 129MV. There was no
significant difference in duration of illness between the two
codon 129 genotype groups.
Intriguingly, the data presented here relates to 54 female
affected patients but only 30 males (P= 0.01, binomial test
given a predicted proportion of 0.5). As a consequence
of this discrepancy, individuals included here were much
more likely to have inherited the mutation from their
mothers than from their fathers, where such information
was available (54 affected mothers, 19 affected fathers,
P= 1 104). The 30 affected males transmitted the muta-
tion to 4 sons and 13 daughters. The 54 affected females
transmitted the mutation to 24 sons and 31 daughters. This
sex distortion was not significant. A similar effect was also
reported in 6-OPRI IPD (53 affected females versus only
33 males, P= 0.008, binomial test) (Mead et al., 2006) and
when combined with these data, the overall significance
was more marked (109 affected females versus 65 males,
P= 0.001). In addition, the proportion of females to males
with both mutations was similar (1.6 : 1 in 6-OPRI, 1.9 : 1
in P102L). No differences were found in terms of age at
onset or death when comparing male and female affected
patients or indeed when comparing those who inherited the
mutation from their mothers versus those who inherited
it from their fathers.
Neither age at onset nor duration of illness was signifi-
cantly different between patients with a predominantly
cognitive or psychiatric versus those with predominantly
cerebellar or motor onset. There was no correlation of
codon 129 genotype with these subgroups of cognitive/
psychiatric compared with the peripheral/cerebellar onset
groups, although numbers were small and in many patients
the codon 129 was unavailable (n= 22/44 with missing
genotype data).
Electroencephalography
A total of 16 individuals had EEG performed after disease
onset and 13 of these demonstrated non-specific abnorm-
alities. All of these abnormal studies were in the context
of significant cognitive impairment or psychiatric symp-
toms and were performed between 6 months and 3 years
after onset. One of these individuals also had widespread
epileptiform discharges with no apparent clinical correlates.
Three further studies were reported as normal. These
were 2–3 years after symptoms developed, although none of
these patients demonstrated significant cognitive or psy-
chiatric symptoms or signs at the time of the study, each
having a predominantly cerebellar syndrome. In one patient
(VII.8) an EEG was performed many years before symptom
onset when the neurological examination was unremark-
able. This was also a normal study, although a repeat 1 year
after onset of predominantly cognitive symptoms was
mildly, though non-specifically, abnormal, with no periodic
sharp wave complexes. In a single patient already reported,
periodic sharp wave complexes were found in the context
of a sCJD-like clinical picture (Rosenthal et al., 1976).
Electromyography and nerve
conduction studies
Ten of the newly reported patients underwent peripheral
neurophysiological studies, eight having nerve conduction
studies (NCS) in combination with EMG, two having
Fig. 5 Clinical features on presentation in P102L IPD.
The relative frequency of cognitive symptoms and signs
on presentation is notable, along with the commonly
occurring peripheral limb symptoms and psychiatric features.
Fig. 6 Clinical features reported during course of P102L IPD.The
high percentage of patients where cognitive deficits were appar-
ent, even if only in later stages, is notable as is the frequency of
sensory signs and lower motor neuron signs. Chorea was not
reported or observed in any of the patients presented.
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NCS only. In all patients the investigations were indicated
by painful sensory symptoms, sometimes accompanied by
areflexia and leg weakness at the time of the study. Of the
10 patients who had NCS, 2 had evidence of a mild axonal
sensorimotor neuropathy. In the other eight, no abnorm-
alities were picked up on NCS in spite of symptoms and
often signs suggestive of peripheral neuropathy. A single
patient had EMG evidence of muscle denervation in combi-
nation with an axonal neuropathy. EMG was normal in
seven others, at least two of whom had objective weakness
of the lower limbs on clinical examination. A single patient
without NCS or EMG abnormalities in spite of painful
sensory symptoms and leg weakness underwent thermal
threshold testing. This demonstrated a defect in the lower
limbs but not in the upper, consistent with either small
fibre neuropathy or central pathway involvement. The
patient was cognitively intact at the time of the investiga-
tion and therefore able to report the sensations accurately.
Overall, there was not a consistent peripheral nerve deficit
to account for sensory symptoms or areflexia.
Neuroimaging
Sixteen of the newly presented patients had neuroimaging.
Fifteen had MRI performed while a further two also had
CT scans. One patient, before the era of routine MRI,
had only a CT. Three of the MRIs demonstrated a degree of
generalized cerebral atrophy out of keeping with the age of
the patient. In one patient, localized cerebellar atrophy
was reported. These were all performed in patients with
significant cognitive and or psychiatric symptoms. Five had
normal MRIs between 1 and 3 years after onset of symp-
toms. In all of these patients, either cognitive or psychiatric
features were absent (four patients) or there were only
subtle cognitive and psychiatric symptoms reported (one
patient).
Interestingly, four patients who had MRI performed were
found to have multiple white matter lesions. In one patient,
the combination of clinical signs and MRI appearances led
to a diagnosis of Binswanger’s disease being made before
the correct diagnosis was reached. All of the CT scans
performed were within normal limits. None of the MRI
scans reported showed any changes associated with prion
disease of other subtypes: the ‘pulvinar’ sign or cortical or
basal ganglia high signal (Fig. 7) (Macfarlane et al., 2007).
Neuropsychology
A total of 11 patients not previously reported had formal
neuropsychological assessment after symptom onset, explor-
ing two or more cognitive domains. In nine of these, evidence
for cognitive deficits with decline from predicted pre-morbid
functioning was elicited, even where bedside assessment
suggested normal cognition. Although two further patients
had no deficits on assessment in spite of clearly symptomatic
disease, no formal assessment of executive function or
attention had been performed in one and full verbal and
performance IQ had not been completed in the other. Deficits
detected on neuropsychological assessment were widespread,
including frontal, subcortical and attentional abnormalities.
However, these deficits were patchy, with no clear consistent
pattern emerging. Three patients with a predominantly psy-
chiatric or cognitive onset (VII.8, VIII.2 and 5.VIII.1)
demonstrated evidence of frontal dysfunction. Patients with
a predominantly cerebellar onset performed better on these
tests, providing objective evidence for the distinction.
Cerebrospinal fluid
Nine individuals had CSF taken for analysis. In one patient
there was borderline elevation of protein. In this patient
oligoclonal bands were reported although no record of
a serum sample for comparison has been found. In all other
patients where CSF was examined, the samples were
acellular with normal protein and glucose levels. In only
three patients was CSF examined for the presence of the
14-3-3 protein, a non-specific marker of neuronal cell
death, which is nonetheless useful in the diagnosis of sCJD
(Sanchez-Juan et al., 2006). 14-3-3 was positive and s100b
was elevated in two of these 14-3-3-positive patients, while
in the third, s100b and neuron-specific enolase were
Fig. 7 MRI findings in P102L IPD. (A) Sagittal T1-weighted image (of 2.VII.2) showing cerebellar atrophy. (B) and (C) Axial T2-weighted
images (of VI.2) showing multiple white matter lesions in the basal ganglia. Similar findings were found in two other patients leading
in one to a diagnosis of Binswanger’s disease being made in combination with the clinical picture. These findings are probably incidental
but the possibility of a link to P102L IPD remains.
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elevated but 14-3-3 protein was not detected. The P102L
IPD patients with positive 14-3-3 were clinically hetero-
geneous, one being a rapid onset patient where sCJD was
considered in the differential, the other being a slowly
progressive cerebellar syndrome.
Non-PRNP genetic modifiers
The APOE genotype was ascertained in 22 patients. Surpris-
ingly, this demonstrated a later onset of disease in individ-
uals having at least one E4 allele, compared with those with
no E4 (linear regression analysis P= 0.015). The APOE and
PRNP codon 129 genotype modify phenotype indepen-
dently of each other and together contribute to around 37%
of the variability of P102L IPD age at onset (eta-squared
of ANOVA).
Two single nucleotide polymorphisms, known as 1368
and 34296, have been shown to be over-represented in
sCJD patients compared with controls (Mead et al., 2001;
Vollmert et al., 2006). These loci were genotyped in patients
with available DNA to examine for a potential effect on
phenotype in IPD P102L. No evidence for genotype
modifications of age at onset was found.
Neuropathology
A total of 11 patients were available for neuropathological
examination. Varying degrees of atrophy were observed
macroscopically, with brain weights varying from 1200 to
1740 g. Histopathological examination demonstrated spongi-
form change, astroctyosis and PrP deposition. These three
features, however, were very variable between individuals and
brain regions. Spongiform change was present in some brain
regions in the majority, but not all, of the patients examined
(7 out of 10 patients) and varied from mild to severe. PrP
deposition was most commonly found in the context of
multicentric amyloid plaques. PrP antibodies ICSM 18 and
ICSM 35 positively labelled these plaques. Multicentric
plaques were commonly found in the molecular layer of the
cerebellum but also less frequently in the granular layer.
Similar plaques were found in the cortex in most patients
examined (9 out of 10 patients) (Fig. 8). In a single patient
(VI.12), the only definite abnormality seen was small
numbers of plaques positively stained with ICSM 18 in the
basal ganglia, although the tissue examined was 20 years old.
More diffuse PrP deposition was demonstrated in the
majority of patients available (7 out of 10). A single patient
(VIII.1) showed very atypical diffuse staining that appeared
to follow cortical tracts and was similar to other IPD patients
but not to previously described P102L pathology.
Clinicopathological comparison demonstrated no clear
association of clinical subtype (cerebellar onset or cogni-
tive onset), disease duration or codon 129 genotype with
severity of spongiform change and degree or type of plaque
deposition. Six PRNP codon 129 MM homozygotes and
four codon 129 MV heterozygotes were included. All the
patients with available post-mortem tissue were of the
common 3,3 APOE genotype. A single atypical patient
(VII.1) with very young onset and prominent dystonia
showed prominent PrP plaque deposition in all areas
examined (including the basal ganglia), with no clear
spongiform change. Findings were not dissimilar from
other, later onset patients. Unfortunately, the atypical
histological patient (VIII.1) had only limited clinical
information available. Two muscle biopsies were also
examined. The findings were non-specific on conventional
stains and no PrP immunoreactivity was demonstrated.
Discussion
The patients presented here constitute by far the largest
study of the classical GSS-associated PRNP mutation,
P102L. Modern investigation, molecular genetic techniques
and advances in pathological examination have allowed us
to revisit a historical British pedigree and other smaller
kindreds. We find evidence of a mutation hot spot at codon
102, a subgroup presenting with rapid cognitive decline and
the significant modification of phenotype by two single
nucleotide polymorphisms.
The microsatellite haplotyping presented here demon-
strates the existence of multiple separate and worldwide
P102L kindreds of UK origin, confirmed in most patients
by established genealogical links that had not been iden-
tified previously. However, the identification of a further six
UK P102L kindreds along with two others of European
origin suggests that multiple mutational events have occur-
red in the recent past. This might be supported by the
identification of at least one of these patients (6.VIII.1) in
an individual without suggestive family history or of known
P102L patients living nearby, suggesting that this might
represent a novel mutation. Given the identification of IPD
Fig. 8 Deposition of abnormal prion protein in cortex and cere-
bellum.The upper panels show characteristic multicentric PrP pla-
ques, stained with the anti-PrP monoclonal antibody, ICSM35 (A+B
from Patient 2.VII. 2).The lower panel shows synaptic deposition of
abnormal PrP (C+D from Patient 7.VIII. 1), demonstrating signifi-
cant pathological heterogeneity. The scaling bar shown in 100mM.
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patients in otherwise typical sCJD presentations, as well as
in patients without a family history of neurodegeneration,
novel mutational events may occur more commonly than
previously thought. The commonest point mutations asso-
ciated with IPD occur at cytosine-phosphate diester-
guanidine dinucleotide sites hypothesized to be mutation
‘hot spots’ in human DNA (Vollmert et al., 2006). These
hot spots are related to the spontaneous demethylation of
cytosine to thymidine. Cytosine-phosphate diester-guani-
dine dinucleotide sites are associated with E200K, D178N
and P102L point mutations, which between them account
for the bulk of IPD patients worldwide (Dagvadorj et al.,
2002; Mead, 2006). An alternative possibility to multiple
separate mutational events being responsible for these
apparently unconnected P102L IPD kindreds is that these
small pedigrees do share a common ancestor with the large
pedigree but that this was long enough in the past for
linkage to the disease haplotype to have broken down. We
estimate a probability of recombination of the 3MB
microsatellite haplotype as about 10% per generation
(assuming a genetic:physical ratio of 3.7).
The unexpected finding that significantly greater num-
bers of females were identified with P102L IPD and the
consequently higher number of individuals having an
affected mother rather than father as the parent from
whom the mutation was inherited is puzzling. This discre-
pancy has been reported once previously in this family,
albeit with smaller numbers of individuals and without
available genetic techniques, allowing the linkage of
kindreds not known to share ancestry (Baker et al., 1985).
It has also been observed in the large 6-OPRI IPD kindred
from the South-East of England (Mead et al., 2006). In
the earlier study in P102L, the finding was explained by
postulating that affected females had significantly more
children than their unaffected siblings and that greater than
half these were daughters. Such an explanation is intriguing,
though hard to explain. Alternatively, because of possible
illegitimacy, we suspected that genealogical research might
more readily identify affected mothers than affected fathers.
In order to consider the possibility of ascertainment bias,
the gender of members of the kindred identified from
parish records or census entries, but who have not been
identified as having suffered from IPD P102L, were
collected. An excess of males in these untraced individuals
was indeed identified. When these were added to the pre-
sumed affected male and female individuals, an excess of
females to males remained (82–68), although this was not
significantly different from an expected proportion of 0.5.
It seems likely that ascertainment bias is responsible for this
gender difference, although the intriguing possibility of
a biological explanation remains.
While the majority of P102L IPD patients here present
with progressive ataxia accompanied by mild or absent
cognitive symptoms and signs, a subset present with a
predominantly cognitive and or psychiatric onset, with mild
or absent cerebellar signs initially. Psychiatric involvement
has been severe enough to necessitate antipsychotic medi-
cation in four patients (VII.1, VII.8, VIII.4 and 3.VIII.1)
and inpatient treatment in two (VII.1 and VII.8). The exis-
tence of these distinct phenotypes (cognitive and psychiatric
versus cerebellar onset) is supported by the finding of
early prominent frontal executive impairment on neuro-
psychology in these patients not seen in other patients so
tested. Neuropsychological assessment is now routine at the
National Prion Clinic but in the past this was more usually
performed only when clinical evidence of cognitive impair-
ment existed. In addition to these neuropsychological
differences, there is a suggestion that the cognitive and
Fig. 9 Photograph of original 1871 asylum entry relating to admission and care of III.3 from Fig. 2. His condition is described as hereditary
and reference is made to his relatives’ care in the same institution.He is reported as being ‘scarcely able to move one leg in front of another’
and his countenance is described as ‘imbecile’. He appears to have had dementia as well as weakness: ‘Can only answer in monosyllables &
then incoherently; is much paralysed’. He was treated with daily doses of brandy until he died. ‘Paralysis’ was listed as the cause on the
death certificate.
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psychiatric presentations have an earlier age at onset and
death. Neuropsychology also highlights, however, that most
if not all patients have cognitive deficits when psychology
is performed, even if the findings are subtle, although
selection bias may limit this conclusion. No pathological
correlates of these two syndrome types have been identified,
although numbers compared are small. Kuru and growth
hormone-associated prion disease are notable for their
onset with cerebellar symptoms (Collinge, 2001), which
prompts speculation that cerebellar onset in P102L might
result from the onset of prion replication outside the
central nervous system. The range of tissue available did not
permit the thorough testing of this hypothesis.
The high degree of clinical heterogeneity and the lack
of characteristic findings on commonly available clinical
neurological investigations make correct diagnosis of P102L
IPD challenging. The finding of positive CSF 14-3-3
combined with the albeit unusual occurrence of periodic
sharp wave complexes on EEG and an sCJD-like pheno-
type in some individuals raises the possibility of missed
diagnosis. It also supports our clinical practice of advising
PRNP analysis routinely in all those presenting with
otherwise undiagnosed pre-senile dementing or ataxic
illnesses.
Peripheral sensory symptoms and muscle weakness
appear almost universal during the course of P102L IPD.
The demonstration of muscle denervation and axonal
sensorimotor neuropathy suggest peripheral neurological
pathology is responsible. Experimental mice over-expressing
wild-type PrP have shown demyelinating peripheral nerve
pathology (Westaway et al., 1994). However, evidence of
peripheral neuropathy in P102L IPD was inconsistent and
where present was axonal, a form that is not uncommon in
the population from unrelated causes. No prion protein
(scrapie isoform) positivity could be demonstrated on two
muscle biopsies examined here and although an indirect
pathological process could still be responsible, peripheral
findings in P102L IPD may be incidental, while sensory
symptoms could be centrally rather than peripherally
driven.
Presented for the first time here is the finding that P102L
IPD patients with methionine homozygosity at codon 129
present significantly earlier than codon 129 heterozygotes.
Earlier age at onset is well recognized in codon 129 homo-
zygotes in other IPD mutations (Collinge et al., 1992; Poulter
et al., 1992; Mead et al., 2006), although the association with
IPD associated with point mutations rather than OPRIs is
less clear (Dlouhy et al., 1992). The less strong effect in P102L
with respect to 6-OPRI may explain why this observation has
not been made before where smaller numbers of patients have
been examined (Hainfellner et al., 1995; Barbanti et al., 1996).
There are several possible mechanisms of action of codon 129
genotype on clinical phenotype. It has long been known that
the interaction between prion protein, scrapie isoform
(PrPSc) and prion protein, normal cellular isoform (PrPc)
occurs most efficiently when the proteins have an identical
primary structure (Palmer et al., 1991); therefore, prion
replication may occur more rapidly and clinical onset earlier
in 129MM individuals. As a further complexity, the primary
structure of PrP determines the permissible conformations of
PrPSc. The extent to which a pathogenic 102L-129M PrP
conformer is permitted by wild-type PrPc with 129V or 129M
may also be important [see Collinge, 2007 for a recent review
(Collinge and Clarke, 2007)]. 102L-129M PrP may be able to
adopt several different pathogenic conformations, which may
be permissible to a greater or lesser extent by the wild-type
protein (Parchi et al., 1998; Hill et al., 2006). The involvement
of wild-type protein is known to be a variable phenomenon in
P102L and a possible determinant of phenotype (Wadsworth
et al., 2006).
The identification of the P102L mutation on a methio-
nine allele in all of the patients presented here with
adequate haplotype data probably relates simply to the fre-
quency of this allele in the background population. P102L
patients existing on a codon 129 valine allele have been
reported, apparently occurring in the context of a distinct
phenotype with prominent psychiatric features and seizures,
different from classical P102L codon 129 methionine
patients (Young et al., 1997; Bianca et al., 2003). Such a
phenotypic difference could relate to different prion strain
propagation originating from the valine allele.
Genotype–phenotype correlations presented here, cor-
rected for codon 129, demonstrate an effect of APOE
genotype on age at onset, with individuals carrying the
E4 allele having a significantly later age at onset than those
without. While this evidence appears in contrast to the
strong association of E4 with risk of Alzheimer’s disease
(Corder et al., 1993) and to published work on the possible
impact of APOE polymorphisms in sCJD showing an over-
representation of the E4 allele in sCJD patients (Amouyel
et al., 1994; Van Everbroeck et al., 2001), such findings have
not been replicated in all published studies (Nakagawa
et al., 1995; Zerr et al., 1996) nor in our own observations
(387 sCJD patients versus unaffected controls, unpublished
data). Recent reports present a similar result in frontotem-
poralobar degeneration, with later disease onset in those
with the APOE E4 genotype in the context of progranulin
mutations (Gass et al., 2006; Beck et al., 2008). APOE may
thus have contrasting effects in the context of different
neurodegenerative disease types.
Most of the P102L IPD patients shared common features
on pathological analysis. Spongiform change, astrocytosis
and PrP deposition, both as multicentric plaques and
synaptic deposits, were seen in the majority. However, the
degree of severity of spongiform change and plaque deposi-
tion were very variable. This did not seem to correlate with
age at onset or duration of illness. Neither did predomi-
nantly cerebellar or cognitive clinical presentations seem to
correlate with pathological findings. PRNP codon 129 MM
homozygotes and MV heterozygotes were equally repre-
sented in the pathology series but no significant differences
were seen between these two groups. However, the small
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numbers in each subgroup and the age of some of the
samples examined (with tissue up to 30 years old) may
prevent correlations from being made. A single highly
atypical clinical patient showed no significant histological
differences from the rest of the series, while an atypical
pathological patient has limited clinical data, although what
is known about this individual is not obviously different
from the other patients examined. These results suggest no
clear clinicopathological correlations, but sample size was
necessarily small.
Immunoblots of proteinase K-digested brain homogenate
from P102L patients demonstrate a spectrum of involve-
ment of protease-resistant wild-type PrP in P102L IPD
(Wadsworth et al., 2006). Four of the seven P102L IPD
patients examined in this study were negative for prion
protein (scrapie isoform), which most probably relates to
sampling issues and the differing density of PrP deposition
in tissue samples both within and between patients. Our
large study therefore does not expand the existing data and
we were unable to test whether protease-resistant PrP
diversity might contribute to clinical heterogeneity. This
remains a plausible concept in IPD that requires a large
series of fresh frozen brain tissue and molecular analysis of
PrP type following partial protease digestion.
The need for public health control measures, together with
the evident diagnostic challenges that IPD heterogeneity
causes, make a strong argument for including PRNP gene
analysis in the list of investigations for suspected prion
disease of any type and indeed of all undiagnosed familial
dementia or cerebellar syndromes. Successful diagnosis
allows clinicians to provide more accurate prognostic infor-
mation to patients, to allow participation in the clinical trials
and reduce the risk of iatrogenic transmission of disease. As a
consequence of these geographically highly mobile ancestors,
and the large number of untraced individuals in the
nineteenth century who were clearly at risk of inheriting
the P102L mutation, it remains likely that further patients
and at-risk individuals exist who have yet to be identified. It
is hoped that the data presented here will help to raise
awareness of P102L IPD and its associated presentations.
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